Investigators presented final six-month data from the EPILOG trial of Centocor Inc.'s ReoPro GPIIb/IIIa inhibitor in all comers undergoing angioplasty. As reported Sunday at the American Heart Association meeting in New Orleans, the composite end point of death, myocardial infarction and repeat revascularization was statistically significant at six months, maintaining the benefit seen at 30 days.

The number of deaths and heart